Century Therapeutics (IPSC) Share-based Compensation (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Share-based Compensation data on file, last reported at $1.4 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $1.4 million, down 40.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.9 million (down 50.8% YoY), and the FY2025 annual result was $6.8 million, down 46.09% from the prior year.
• Share-based Compensation grew to $1.4 million in Q1 2026 per IPSC's latest filing, from $1.3 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $4.0 million in Q3 2023 and troughed at -$7.9 million in Q4 2022.
• A 5-year average of $2.1 million and a median of $2.8 million in 2022 frame the typical range for Share-based Compensation.
• On a YoY basis, Share-based Compensation climbed as much as 2405.26% in 2022 and fell as far as 584.49% in 2022.
• A 5-year view of Share-based Compensation shows it stood at -$7.9 million in 2022, then soared by 144.94% to $3.6 million in 2023, then declined by 25.32% to $2.7 million in 2024, then slumped by 51.13% to $1.3 million in 2025, then gained by 11.15% to $1.4 million in 2026.
• Business Quant data shows IPSC's Share-based Compensation at $1.4 million in Q1 2026, $1.3 million in Q4 2025, and $891000.0 in Q3 2025.